Amneal Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net loss | $(73,876) | $(48,722) | $(254,789) |
| Less: Net (income) loss attributable to non-controlling interests | (43,010) | (35,271) | 125,241 |
| Net loss attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest | (116,886) | (83,993) | (129,548) |
| Accretion of redeemable non-controlling interest | — | — | (438) |
| Net loss attributable to Amneal Pharmaceuticals, Inc. | (116,886) | (83,993) | (129,986) |
| Other comprehensive (loss) income: | |||
| Foreign currency translation adjustments arising during the period | (5,788) | (1,059) | (26,891) |
| Unrealized (loss) gain on cash flow hedge, net of tax of $0 | (1,168) | (48,497) | 97,059 |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | (26,205) | (3,366) | — |
| Less: Other comprehensive loss (income) attributable to non-controlling interests | — | 9,875 | (35,292) |
| Other comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. | (33,161) | (43,047) | 34,876 |
| Comprehensive loss attributable to Amneal Pharmaceuticals, Inc. | $(150,047) | $(127,040) | $(95,110) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.